09:47 AM EDT, 03/14/2024 (MT Newswires) -- Charles River Laboratories International ( CRL ) and Navega Therapeutics have entered into a partnership for the production of the NT-Z001 adeno-associated virus-based gene therapy for phase 1 clinical trials, the companies said Thursday.

The production program agreement will give Navega access to Charles River's gene therapy contract development and manufacturing capabilities to bring NT-Z001 to clinic, according to the companies.

Price: 262.15, Change: +0.97, Percent Change: +0.37